|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,993,830: Glucagon-Like Peptide-1 Receptor Agonists
U.S. Patent 5,993,830, titled "GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS," issued on November 30, 1999, to Novo Nordisk A/S. The patent claims a series of substituted exendin derivatives as GLP-1 receptor agonists. These compounds are investigated for their therapeutic utility in treating conditions such as diabetes mellitus and obesity. The patent landscape surrounding GLP-1 receptor agonists is highly competitive, with multiple entities holding key patents for different classes of compounds, manufacturing processes, and therapeutic applications.
What Does U.S. Patent 5,993,830 Claim?
The primary claims of U.S. Patent 5,993,830 focus on novel chemical entities and their use. The patent claims cover:
- Compound Claims: Specifically, the patent claims substituted exendin derivatives. These are modifications of the naturally occurring exendin-4 peptide, designed to improve pharmacokinetic properties such as stability and duration of action. The general structure described in the claims encompasses specific substitutions at various positions within the exendin sequence.
- Claim 1 defines a substituted exendin, which is an exendin peptide having at least one amino acid residue replaced by a different amino acid residue. The claim further specifies positions and types of substitutions, aiming for improved receptor binding affinity and biological activity.
- Dependent claims refine these substitutions, detailing specific amino acid replacements at defined positions (e.g., positions 2, 14, 20, 22, 25, 28, 31, 34, 35, 36, 37, 39, 40, and 41 of the exendin sequence). These detailed claims create a specific chemical space around the core exendin structure.
- Pharmaceutical Composition Claims: Claims related to pharmaceutical compositions containing at least one of the claimed substituted exendin derivatives. These compositions are formulated for administration to a subject, typically in a therapeutically effective amount.
- Method of Treatment Claims: Claims outlining methods of treating conditions such as diabetes mellitus, impaired glucose tolerance, and obesity. The method involves administering a therapeutically effective amount of a claimed substituted exendin derivative to a subject in need thereof.
The exendin peptide backbone is derived from exendin-3 or exendin-4, both found in the saliva of the Gila monster. The patent's innovation lies in modifying this peptide to create agonists with enhanced therapeutic profiles compared to native GLP-1 or exendin-4.
Who is the Assignee of U.S. Patent 5,993,830?
The assignee of U.S. Patent 5,993,830 is Novo Nordisk A/S. Novo Nordisk is a global healthcare company with a long-standing focus on diabetes care and is a major player in the development of GLP-1 receptor agonists. This patent represents an early foundational piece of intellectual property in their development of this therapeutic class, contributing to their portfolio of blockbuster drugs like liraglutide and semaglutide.
What is the Prior Art Relevant to U.S. Patent 5,993,830?
The prior art at the time of filing (Application filed: May 20, 1997) for U.S. Patent 5,993,830 would have included:
- Discovery and characterization of GLP-1: Glucagon-like peptide-1 (GLP-1) was identified as an incretin hormone with potent insulinotropic effects. Its short half-life in vivo was a known limitation for therapeutic use.
- Discovery and characterization of Exendin-3 and Exendin-4: These peptides, isolated from Gila monster saliva, were found to bind to the GLP-1 receptor and exhibit GLP-1-like activity. Exendin-4, in particular, demonstrated higher receptor affinity and a longer duration of action compared to GLP-1.
- Early attempts at peptide modification: Research was ongoing to engineer GLP-1 and exendin analogs with improved metabolic stability and prolonged half-lives, often through modifications like pegylation or amino acid substitutions.
- Existing diabetes treatments: The landscape included insulin therapy, sulfonylureas, metformin, and other agents, establishing a need for novel mechanisms of action.
The patent distinguishes itself by proposing specific substitutions on the exendin scaffold that confer improved properties, moving beyond simply identifying exendin as a receptor agonist. The detailed chemical structures and specific amino acid modifications claimed are critical to defining the patent's novelty and inventive step over existing exendin sequences or general peptide modification strategies.
What is the Patent Landscape for GLP-1 Receptor Agonists?
The patent landscape for GLP-1 receptor agonists is extensive and features multiple key players. U.S. Patent 5,993,830 is one of the earlier patents in this field.
Key Companies and Their Contributions:
- Novo Nordisk: Holds foundational patents like U.S. Patent 5,993,830, covering early exendin analogs. They have since developed and patented numerous iterations, including liraglutide (Victoza, Saxenda) and semaglutide (Ozempic, Rybelsus, Wegovy), which are protected by a robust patent portfolio covering compound structure, formulations, delivery devices, and manufacturing processes.
- Eli Lilly and Company: A significant competitor with patents covering exenatide (Byetta, Bydureon), which is synthetic exendin-4. Lilly also has its own portfolio of GLP-1 receptor agonists, including tirzepatide (Mounjaro), a dual GLP-1/GIP receptor agonist, protected by separate patent families.
- Amgen: Previously held patents related to certain GLP-1 analog structures and delivery systems.
- Takeda Pharmaceutical Company: Has also been active in this space, though less dominant than Novo Nordisk or Lilly.
- AstraZeneca: Entered the market with the development of dulaglutide (Trulicity).
Key Patenting Strategies:
- Compound Patents: Protecting novel chemical structures of GLP-1 analogs. U.S. Patent 5,993,830 exemplifies this.
- Formulation Patents: Developing new ways to deliver the peptides, such as sustained-release formulations (e.g., Bydureon, which uses the Durasphere microsphere technology) or oral formulations (e.g., Rybelsus).
- Delivery Device Patents: Protecting injection pens and other devices that facilitate convenient administration.
- Manufacturing Process Patents: Developing scalable and cost-effective methods for synthesizing complex peptide drugs.
- Method of Use Patents: Claiming specific therapeutic indications or patient populations for existing compounds.
- Combination Therapy Patents: Protecting formulations or treatment regimens involving GLP-1 agonists in combination with other antidiabetic agents.
The expiration of early foundational patents, such as those covering the original exenatide and liraglutide structures, has paved the way for generic competition. However, ongoing innovation in next-generation compounds, delivery systems, and dual agonists continues to be protected by extensive patent filings, maintaining a competitive and dynamic intellectual property environment. U.S. Patent 5,993,830, while expired, represents an important early development that contributed to this expansive field.
What is the Status and Potential Impact of U.S. Patent 5,993,830?
U.S. Patent 5,993,830 expired on November 30, 2019. As an expired patent, its claims are no longer enforceable.
Impact:
- Foundational Contribution: The patent was instrumental in laying the groundwork for Novo Nordisk's significant presence in the GLP-1 receptor agonist market. The compounds claimed likely served as precursors or exemplars for later, commercially successful molecules.
- Opening the Field: By securing intellectual property rights for specific modifications of exendin, Novo Nordisk helped to validate and advance the concept of using engineered exendin peptides as therapeutic agents for diabetes and obesity. This encouraged further research and development across the industry.
- Limited Direct Impact Today: With its expiration, the specific claims of U.S. Patent 5,993,830 no longer prevent other companies from synthesizing or using the claimed compounds, provided they do not infringe on other, still-active patents. However, the broader scientific and technical knowledge generated by the patent continues to inform the field. The compounds that were claimed may be superseded by more advanced analogs with superior efficacy, safety, or pharmacokinetic profiles, which are themselves protected by more recent patents.
The expiration of this patent signifies a maturing phase for the initial generation of exendin-based GLP-1 receptor agonists. The focus for innovation and patent protection has shifted to next-generation molecules, novel delivery mechanisms, and combination therapies.
How Do the Claims of U.S. Patent 5,993,830 Compare to Modern GLP-1 Receptor Agonists?
U.S. Patent 5,993,830 claims substituted exendin derivatives. These are peptide-based molecules that mimic the action of the endogenous GLP-1 hormone. Modern GLP-1 receptor agonists (GLP-1 RAs) represent an evolution from the early structures.
Comparison Points:
- Peptide Structure:
- U.S. Patent 5,993,830: Claims modified exendin peptides. Exendin-4 is a 39-amino acid peptide. The patent claims specific amino acid substitutions at various positions to enhance stability and efficacy. For example, substitutions might aim to prevent enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) or increase half-life through other mechanisms.
- Modern GLP-1 RAs: While many modern GLP-1 RAs, like liraglutide and semaglutide, are still based on modified exendin-4 or GLP-1 structures, they often incorporate more sophisticated modifications. These can include:
- Acylation: Attachment of fatty acid chains (e.g., C16 or C18 fatty acid) to increase albumin binding and thus prolong half-life.
- Non-peptide Components: Though less common for true GLP-1 RAs, research into small molecule agonists exists, representing a different chemical class entirely.
- Fusion Proteins: Large molecules designed for very long-acting effects.
- Half-Life and Dosing Frequency:
- U.S. Patent 5,993,830: The modifications in this patent aimed to improve upon the half-life of native GLP-1 and likely exendin-4. However, the resulting compounds may still have required more frequent dosing (e.g., once or twice daily) compared to some of the ultra-long-acting agents available today.
- Modern GLP-1 RAs: This is a major area of advancement. Semaglutide, for instance, has a half-life of approximately one week, enabling once-weekly subcutaneous injection. Oral semaglutide also exists. Tirzepatide, a dual agonist, has a half-life of about five days.
- Therapeutic Indications and Efficacy:
- U.S. Patent 5,993,830: Primarily focused on diabetes and obesity.
- Modern GLP-1 RAs: While diabetes and obesity remain primary indications, newer agents have demonstrated significant cardiovascular benefits (e.g., reduced risk of major adverse cardiovascular events). They also show substantial weight loss potential.
- Dual Agonists:
- U.S. Patent 5,993,830: Claims single receptor agonists targeting the GLP-1 receptor.
- Modern GLP-1 RAs: The landscape now includes dual and even triple agonists targeting multiple related receptors. Tirzepatide targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This offers potentially greater efficacy in glucose lowering and weight loss.
In essence, U.S. Patent 5,993,830 represents an early, vital step in the development of peptide-based GLP-1 receptor agonists. Modern GLP-1 RAs build upon this foundation with more advanced chemical engineering, leading to vastly improved dosing convenience, broader therapeutic benefits, and more potent effects.
Key Takeaways
- U.S. Patent 5,993,830 claims substituted exendin derivatives as GLP-1 receptor agonists, primarily for treating diabetes and obesity.
- The patent was issued to Novo Nordisk A/S on November 30, 1999.
- The patent expired on November 30, 2019, meaning its claims are no longer enforceable.
- The patent's claims are focused on specific chemical structures of modified exendin peptides, representing early innovation in the field of peptide therapeutics for metabolic diseases.
- The patent landscape for GLP-1 receptor agonists is extensive, with Novo Nordisk and Eli Lilly being dominant players holding patents on various compound classes, formulations, and delivery systems.
- Modern GLP-1 receptor agonists, while often built on similar peptide backbones, incorporate more advanced modifications (e.g., acylation, fusion proteins) and include dual agonists, leading to improved pharmacokinetic profiles, enhanced therapeutic benefits, and broader indications compared to the compounds initially claimed in U.S. Patent 5,993,830.
Frequently Asked Questions
- Can I produce or sell compounds claimed in U.S. Patent 5,993,830 now that it has expired?
While the specific claims of U.S. Patent 5,993,830 are no longer enforceable due to patent expiration, the production and sale of such compounds are still subject to infringement of other potentially active patents covering manufacturing processes, formulations, or specific therapeutic uses. A thorough freedom-to-operate analysis is required.
- What is the significance of exendin derivatives claimed in this patent for modern drug development?
The exendin derivatives claimed in this patent represent foundational work in developing peptide-based GLP-1 receptor agonists. They established the principle of modifying natural peptides to achieve improved therapeutic properties, paving the way for more sophisticated next-generation drugs.
- Does the expiration of U.S. Patent 5,993,830 mean that drugs based on its claims are now generic?
The expiration of this patent means the specific chemical structures it claimed are no longer protected. However, commercially successful drugs, such as liraglutide or semaglutide, are protected by their own, more recent patent families covering the specific molecular entity, formulation, manufacturing, and method of use. Generic versions of these drugs become available only after all relevant patents expire.
- What were the primary innovations claimed by U.S. Patent 5,993,830 over prior art?
The primary innovations were specific, defined amino acid substitutions on the exendin peptide backbone, which were claimed to confer improved receptor binding affinity, increased biological activity, and enhanced metabolic stability compared to naturally occurring GLP-1 or unmodified exendin peptides.
- Who are the main competitors in the GLP-1 receptor agonist market besides Novo Nordisk?
Eli Lilly and Company is a major competitor, with exenatide and tirzepatide. AstraZeneca also has a significant presence with dulaglutide. Several other pharmaceutical companies are developing or have marketed compounds within this therapeutic class.
Citations
[1] Jensen, B. L., Jonassen, I., Knudsen, L. B., Møller, K. T., & De Courten, M. (1999). Glucagon-like peptide-1 receptor agonists (U.S. Patent No. 5,993,830). U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
